Form 4: NeuroMetrix Director Van Avermaete Receives Restricted Stock Units

Director David Van Avermaete was granted 13,730 restricted stock units in NeuroMetrix, Inc. on May 22, 2024, vesting on the earlier of the 2025 annual meeting or a change in control.

Summary

• David Van Avermaete, a director of NeuroMetrix, Inc., received 13,730 restricted stock units on May 22, 2024.
• The restricted stock units will vest 100% on the earlier of the date of the 2025 annual meeting of stockholders or a change in control of NeuroMetrix, Inc.
• Vesting is contingent upon Van Avermaete's continued service on the Board of Directors.
• The exercise price of the restricted stock units is $4.37, based on the Nasdaq market price on April 30, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of restricted stock units is a standard practice and indicates confidence in the company's future, but it's not a major event.

Positives

• The grant of restricted stock units aligns the director's interests with those of the shareholders.
• The vesting conditions incentivize continued service and commitment to the company's success.

Future Outlook

The restricted stock units will vest on the earlier of the 2025 annual meeting of stockholders or a change in control of the Issuer, subject to the Reporting Person's continued service on the Board of Directors on such date.

Industry Context

Equity compensation is a common practice for aligning the interests of company directors with those of shareholders, particularly in growth-oriented companies like NeuroMetrix.

Comparison to Industry Standards

• Granting restricted stock units to directors is a standard practice in publicly traded companies to incentivize performance and align interests with shareholders.
• The vesting schedule, contingent on continued service and a potential change in control, is typical for such grants.
• Comparable companies in the medical technology sector, such as Masimo or Insulet, also utilize equity compensation for their board members.

Stakeholder Impact

• Shareholders may view the grant positively as it aligns the director's interests with the company's long-term success.
• The director is incentivized to contribute to the company's growth and performance.

Key Dates

Keywords

NeuroMetrix, Restricted Stock Units, Director, Van Avermaete, NURO, Equity Compensation, Form 4